Introduction
============

Both ischemic myocardial infarction and ischemic stroke are the leading causes of disability and death of cardio-cerebral vascular diseases ([@B5]). One of the causes is ischemia and reperfusion--induced tissue or organ injury, leading to morbidity and mortality in a wide-range of pathologies ([@B24]). Diverse pathological factors, such as inflammation ([@B41]), oxidative stress ([@B39]), and apoptosis ([@B46]) compose the underlying pathological mechanism of MIRI. Although restoring the blood reperfusion as soon as possible will contribute to attenuate cerebral ischemic injury in clinic, the following reperfusion can also cause cerebral edema, brain hemorrhage, and neuronal death, resulting in brain injury ([@B75]). Multiple mechanisms are involved in cerebral ischemia/reperfusion injury (CIRI), including free radical-induced inflammation, energy metabolism disorder, excitotoxicity, abnormal opening of blood--brain barrier, oxidative stress, and calcium overload ([@B85]; [@B39]; [@B13]; [@B18]; [@B50]; [@B71]). Traditional Chinese medicine (TCM) has been widely prescribed in clinics in China and some Asian countries for more than 2000 years. Studies over the past decades revealed that certain TCM and their major active ingredients have a protective and therapeutic effect on I/R-induced injury in brain and heart ([@B30]).

Ginkgo biloba extracts (EGB, especially EGb761 and EGb50) are among the most popular herbal dietary supplements, frequently applied for multiple cardio-cerebral vascular indications ([@B118]). A recent search of PubMed with the keyword combinations of "Ginkgo biloba AND brain" or "Ginkgo biloba AND heart" yielded 579 or 145 reports, respectively. For brain-related diseases, EGB is reported to have a beneficial effect on acute cerebral infarction ([@B106]), chronic cerebral hypoperfusion ([@B35]), brain damage ([@B91]), ischemic stroke ([@B10]; [@B66]), hippocampal neuronal loss ([@B79]; [@B92]), cognitive impairment ([@B4]), memory deficit ([@B70]; [@B2]), dementia ([@B20]), Parkinson's disease ([@B89]) and Alzheimer's disease ([@B84]; [@B48]), with its mechanisms of action such as resisting apoptosis, oxidative stress, inflammatory response, immune response and platelet activation ([@B36]; [@B87]; [@B12]; [@B22]; [@B62]). In addition, EGB also exerts protective effect on heart-related diseases, including cardiac injury ([@B6]), arrhythmia ([@B114]), myocardial ischemia ([@B97]), myocardial infarction ([@B47]; [@B51]) and doxorubicin-induced cardiotoxicity ([@B67]) mainly via antioxidant, anti-apoptotic, anti-inflammation, and anti-mitochondrial oxidative damage. Furthermore, numerous studies reported that EGB could attenuate both MIRI ([@B31]; [@B83]; [@B45]; [@B37]; [@B82]; [@B53]) and CIRI ([@B33]; [@B80]; [@B113]; [@B110]). The most two recent reports demonstrated that EGB could reduce MIRI via TLR-4/NF-κB signaling pathway ([@B90]) and ameliorate cardiac hypertrophy via activation of muscarinic receptors (M2)/nitric oxide (NO) pathway ([@B60]). The main identified pharmacological active ingredients are flavonols (kaempferol, quercetin, myricetin, apigenin, isorhamnetin, luteolin, and tamarixetin) and terpene trilactones (ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J, ginkgolide M, ginkgolide K, ginkgolide L, ginkgolide P, ginkgolide Q, and bilobalide) ([@B93]; [@B42]; [@B62]). Shuxuening injection (SXNI), one of the pharmaceutical preparations of EGB, is a Sino Food and Drug Administration (SFDA)-approved Chinese Materia Medica consisting of Ginkgo flavonol glycosides and Ginkgolides applied widely for ischemia stroke and coronary heart disease (CHD) in clinic in China ([@B111]; [@B117]; [@B29]; [@B95]; [@B55]; [@B14]), which might improve critical ischemia and decrease reperfusion injury.

Moreover, an increasing number of studies began to focus on brain-heart connection ([@B7]; [@B16]; [@B26]). In previous studies, we have explored that endothelial cell inflammation therapy might serve as a common underlying mechanism of another Chinese Materia Medica, Danhong injection (DHI), for stroke and coronary artery disease (CAD) treatment, using an integrated network pharmacology and experimental verification approach ([@B56]). In addition, we have also reported that reinstating neuronal arginine vasopressin (AVP) level was one of the shared mechanisms contributing to protection of neuronal and cardiac cells from oxygen-glucose deprivation injury by DHI ([@B109]). Since the reported effects of Ginkgo biloba extracts on brain and heart were diverse and sometimes controversial, and the involved molecular mechanisms were not clear, we employed a comparative transcriptome method in the present study to explore the common and differential effects and the underling mechanisms of Shuxuening injection (SXNI) on both myocardial ischemia-reperfusion injury (MIRI) and cerebral ischemia-reperfusion injury (CIRI). Our new findings may shed new light on the clinical and pharmacological application for SXNI, and may facilitate a better understanding of detailed mechanisms of I/R injury in brain and heart and discovering natural product-derived agents for co-treatment of cardio-cerebral diseases.

Materials and Methods {#s1}
=====================

Drugs and Reagents
------------------

Shuxuening injection (drug approval number: Z13020795; batch number: 15101201) was provided by China Shineway Pharmaceutical Group Ltd. (Shijiazhuang, China). The chemical content of a SXNI (5 mL/unit), containing 4.2 mg total Ginkgo flavonol glycosides and 0.7 mg Ginkgolides, is equal to 17.5 mg Ginkgo biloba leaf extract according to manufacturer's instruction. Valsartan (drug approval number: H20040217) was purchased from Beijing Novartis Pharma Ltd. (Beijing, China). 2,2,2-Tribromoethanol was purchased from Sigma (T48402, St. Louis, MO, United States). 2,3,5-Triphenyl-2H-Tetrazolium Chloride (TTC) was purchased from Solarbio (T8170, Beijing, China). Hematoxylin and eosin (H&E) staining kit was purchased from Beyotime Biotechnology (C0105, Shanghai, China). ELISA kits for Lactate dehydrogenase (LDH), Aspartate aminotransferase (AST), Creatine kinase-MB (CK-MB) and Creatine kinase (CK) were purchased from Biosino Bio-Technology and Science Inc. (Beijing, China).

Animals
-------

Male C57BL/6J mice (22 ± 2 g) were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China, Certificate no.: SCXK Jing 2012-0001). This study was carried out in accordance with the recommendations in the Guidance for the Care and Use of Laboratory Animals issued by the Ministry of Science and Technology of China and the protocol approved by the Laboratory Animal Ethics Committee of Tianjin University of TCM (Permit Number: TCM-LAEC2014004). The animals were housed in cages at a temperature of 22 °C ± 2°C and humidity of 40% ± 5%, under a 12-h light/dark cycle, with free access to food and water. In the previous experiments, animals were randomized into several groups. The experimental procedures were according to the European Union (EU) adopted Directive 2010/63/EU, and all animals were administrated following the guidelines of Tianjin University of TCM Animal Research Committee (TCM-LAEC2014004).

MIRI Model and Drug Administration
----------------------------------

The mouse MIRI model was performed as previously described ([@B27]). Briefly, mice were anesthetized intraperitoneally with 1.5% Tribromoethanol (150 mg/kg) and then placed in a supine position. For myocardial ischemia model preparation, the chest was opened via a left thoracotomy through the intercostal space between 3 and 4 sternal rib, and the heart was exposed. A slipknot was tied around the left anterior descending (LAD) coronary artery 1--2 mm under left auricle utilizing a 7-0 silk suture. Then the thorax was closed, and as soon as spontaneous respiration was sufficient, the mice were released and allowed to recover on an electric blanket. After 30 min of ischemia, the slipknot was released and followed by 24 h of reperfusion. ST-segment elevation on an electrocardiogram monitor represented a success in MIRI model surgery. Sham-operated animals were subjected to the same surgical procedures without ligating LAD coronary artery. The mice were randomly divided into four or five groups in the following experiments:Sham, I/R, I/R+SXNI (medium dose, 2.5 mL/kg), I/R+SXNI (high dose, 12.5 mL/kg) and I/R+valsartan (20 mg/kg). SXNI were administered via tail intravenous injection within 10 min after the beginning of ischemia, and valsartan via gavage pre-administration for 1 week. Sham and I/R groups were intravenous administered with 0.9% normal saline. No difference was observed in surgical mortality among groups investigated. At 24 h hours after reperfusion, the heart was quickly excised, frozen at -70°C, and the ventricular tissue below the ligation was cut into four slices perpendicular to the long axis of the heart. The heart sections were then incubated in a 24-well culture plate with 1% TTC solution at 37°C for 15 min, respectively. After staining by TTC, red parts in the heart indicated ischemic but viable tissue, while pale areas represented infarcted myocardium. Images were digitally captured using a microscope (S8APO, Leica, Solms, Germany), and infarct size areas were determined with planimetry software (Image J; National Institutes of Health, Bethesda, MD, United States). The size of infarction area was expressed as percentage of the ventricle area.

CIRI Model and Drug Administration
----------------------------------

Anesthesia was induced with 2% isoflurane inhalation and then maintained with 1.5% isoflurane in 70% nitrous oxide/30% oxygen after endotracheal intubation and mechanical ventilation by a small animal respirator (RWD, Inc., China). After a midline incision at the neck, the right carotid bifurcation was exposed, and the following external carotid artery (ECA) branches were cut after electrocoagulation: the occipital, the cranial thyroid, the pterygopalatine artery, and the ascending pharyngeal artery. After occlusion of the common carotid artery (CCA) by a micro-clip, the right ECA was ligated and cut distally to the cranial thyroid artery. A silicone-coated 4-0 nylon monofilament (Prolene, Ethicon) was introduced into the ECA and gently advanced through the internal carotid artery (ICA) until its tip occluded the origin of the middle cerebral artery (MCA). Through this, local cortical blood flow in the right MCA territory dropped to 20% of baseline. Then, MCA occlusion (MCAO) mice were then divided into five groups: model (saline), SXNI (low dose, 0.5 mL/kg), SXNI (medium dose, 2.5 mL/kg), SXNI (high dose, 12.5 mL/kg), and edaravone (9 ml/kg). Sham operated mice were processed identically except for MCAO which served as normal control. Mice were treated via intravenous injection once after 90 min of ischemia. The endovascular suture remained in place until reperfusion was allowed by withdrawal of the filament and removal of the micro-clip at the CCA after 120 min of ischemia. After 24 h, ratios of infarct volumes were measured and expressed as a percentage. All mice were euthanized at 24 h after ischemia. Then, the brains were removed and freshly cut (eight 1 mm-thick coronal slices) in a brain matrix device. The brain slices were stained with 2% solution of TTC in 0.9% normal saline at 37°C for 30 min in the dark. After staining, sections were again washed twice in normal saline and fixed with 4% paraformaldehyde for 1 h at room temperature. Ischemic infarct volumes were assessed using Image J analysis.

Echocardiographic Measurement
-----------------------------

Cardiac left ventricular function and coronary blood flow were assessed non-invasively at 18 h after MIRI using an ultra-high resolution small animal ultrasound Vevo 2100 Imaging System (VisualSonics, Toronto, ON, Canada) equipped with a 30 MHz transducer ([@B15]; [@B40]). The mice were anesthetized using 1.5--2.0% isoflurane in O~2~ gas. When fully anesthetized, each mouse was transferred to dorsal recumbency and placed on a heated imaging platform. The following parameters as indicators of cardiac function were measured by M-mode and Color Doppler mode: left ventricular (LV) ejection fraction (EF), LV fractional shortening (FS), cardiac output (CO), stroke volume, LV internal dimensions at diastole (LVIDd), LV internal diameter systole (LVIDs), LV posterior wall diastole (LVPWd), LV posterior wall systole (LVPWs), LV systole volume (LV Vols), LV diastole volume (LV Vold), heart rate and LV mass, along with aortic valve (AV) peak velocity, AV peak pressure and aorta velocity-time integral mean velocity (AoV VTI).

Measurement of Histopathological Examination and Biochemical Parameters
-----------------------------------------------------------------------

Myocardial damage was evaluated by measuring plasma concentration of LDH, AST, CK-MB, and CK, routine indicators for myocardial inflammation and acute myocardial infarction commonly used for clinical diagnostics. At the end of the experiment, blood was collected and serum was separated by centrifugation at 1,000 rpm for 15 min. The biochemical parameters were detected using ELISA kit by automatic biochemical analyzer (Multiskan MK3; Thermo Fisher Scientific, Waltham, MA, United States), according to the manufacturer's instruction as previously described. After collecting the blood samples, the hearts were removed. Heart tissues were fixed in 10% paraformaldehyde solution for more than 48 h, embedded in paraffin, sliced into pieces of 5 μm thick, and stained with H&E. The histopathological changes were detected by optical microscope (Moticam Pro 282A, Motic China Group Co., Ltd., Xiamen, China).

Sample Preparation and Sequencing
---------------------------------

In separate experiments, the left ventricular myocardium sections of MIRI and the brain slices from CIRI with or without SXNI treatment (medium dose) were collected as discovery cohorts for high-throughput sequencing. Total RNA of each sample was extracted with Trizol reagent (Invitrogen, CA) according to the manufacturer's instructions. The RNA concentration, purity and integrity were separately measured using Qubit^®^ RNA Assay Kit in Qubit^®^ 2.0 Fluorometer^®^ (Life Technologies, CA, United States), the NanoPhotometer spectrophotometer (IMPLEN, CA, United States) and the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, Santa Clara, CA, United States). A total amount of 3 μg RNA per sample was used as input material for the RNA sample preparations. The resulting cDNA libraries were generated using NEBNext^®^ Ultra^TM^ RNA Library Prep Kit for Illumina^®^ (NEB, United States) following manufacturer's recommendations and the quality was assessed on the Agilent Bioanalyzer 2100 system. The clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3-cBot-HS (Illumina) according to the manufacturer's instructions. After cluster generation, the library preparations were sequenced on an Illumina Hiseq platform and 125 bp/150 bp paired-end reads were generated.

High-Throughput Data Analysis
-----------------------------

Raw data of fastq format were firstly processed and the clean data were obtained by removing reads containing adapter, reads containing ploy-N and low quality reads from raw data. All the downstream analyses were based on the clean data with high quality. The reference sequences used were genome of *Mus musculus*. Clean reads were, respectively, aligned to the reference genome using Bowtie v2.2.3. HTSeq v0.6.1 was used to count the reads numbers mapped to each gene. And then FPKM, currently the most commonly used method for estimating gene expression levels, was calculated based on the length of the gene and reads count mapped to this gene. Differential expression analysis of two groups was performed using the DESeq R package (1.18.0). log~2~(Fold change) of 1 and *P*-value of 0.05 were set as the threshold for significantly differential expression.

Pathway and Function Analysis of Differentially Expressed Genes (DEGs) Using Ingenuity^®^ Pathway Analysis
----------------------------------------------------------------------------------------------------------

The gene expression data derived from RNA-Seq was used to generate core and functional analysis by Ingenuity^®^ Pathway Analysis (IPA). Genes with cutoffs of fold change ≥ 2 and *p*-Value ≤ 0.05 after SXNI treatment were set to identify and assign the molecules to the Ingenuity's Knowledge Base. Each identifier except the novel transcripts was mapped to its corresponding object in Ingenuity's Knowledge Base. The core and functional analysis were conducted in IPA with the following settings: Ingenuity Knowledge Base as a reference set; endogenous chemicals not included; direct and indirect relationships. Furthermore, canonical pathways and diseases and functions analysis were performed to identified significantly relevant pathways and functions which were considered for further analysis. The significance was measured in two principles: (1) the ratio of the number of molecules from the data set that map to the pathway divided by the total genes of the corresponding pathways, and (2) Fisher's exact test was used to calculate a *p*-value determining the probability.

RNA Extraction and RT-PCR
-------------------------

Total RNA samples were isolated using EasyPure1 RNA Kit (TransGen Biotech, Beijing, China) according to manufacturer's protocols. Reverse transcription was then performed using Transcriptor First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany) to obtain cDNA. A SYBR Green I-based real-time quantitative PCR was conducted to analyze the expression of target gene including tumor necrosis factor receptor superfamily member 12a (*Tnfrsf12a*), interleukin 6 (*IL-6*), collagen type III alpha 1(*Col3a1*) and phospholipase A2 group IIF (*Pla2g2f*). The relative mRNA level was determined using the comparative CT method and was normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*). The primers were synthesized by the Sangon Company (Shanghai, China). Primer sequences were as follows (**Table [1](#T1){ref-type="table"}**).

###### 

Primer sequences.

  Primer name           Primer sequence (5′--3′)
  --------------------- --------------------------
  Tnfrsf12a sense       CCCCAGTACACACGGAAACAA
  Tnfrsf12a antisense   CTCCCTCCCCTCCAAACATTA
  IL6 sense             GCCCACCAAGAACGATAGTCA
  IL6 antisense         ACCAGCATCAGTCCCAAGAAG
  Col3a1 sense          AGCGGCTGAGTTTTATGACG
  Col3a1 antisense      CAGGTGTAGAAGGCTGTGGG
  Pla2g2f sense         TACGGCTGCTACTGCGGG
  Pla2g2f antisense     GTAGACCCCAGCGGGACAT
  GAPDH sense           TGGTGAAGCAGGCATCTGAG
  GAPDH antisense       TGCTGTTGAAGTCGCAGGAG

Statistical Analysis
--------------------

All experiments were expressed as the mean ± SEM or mean ± SD. Statistical analysis Statistical analysis was carried out using Student's two-tailed *t*-test for comparison between two groups and One-way analysis of variance (ANOVA) followed by Dunnett's test the data involved three or more groups. *P* \< 0.05 was defined as significant. All tests were performed using GraphPad Prism 7 software (GraphPad Software, Inc., La Jolla, CA, United States).

Results
=======

SXNI Improved the Cardiac Function in MIRI Mice
-----------------------------------------------

After 30 min of ischemia and 18 h of reperfusion, echocardiography was performed to determine the effects of SXNI on cardiac function. Compared to sham group, I/R group significantly decreased LVEF %, LVFS %, CO, stroke volume, LVPWs, and increased LVIDd, LVIDs, LV Vold, LV Vols, while it had no marked change in heart rate and LV Mass (**Figure [1](#F1){ref-type="fig"}**). By contrast, SXNI (2.5 and 12.5 mL/kg) and valsartan (20 mg/kg) markedly attenuated I/R-induced impairment of LVEF % (**Figure [1B](#F1){ref-type="fig"}**), LVFS % (**Figure [1C](#F1){ref-type="fig"}**), LVIDs (**Figure [1G](#F1){ref-type="fig"}**) and LV Vols (**Figure [1K](#F1){ref-type="fig"}**). SXNI at 12.5 mL/kg also improved the parameters of CO (**Figure [1D](#F1){ref-type="fig"}**), stroke volume (**Figure [1E](#F1){ref-type="fig"}**), LVIDd (**Figure [1F](#F1){ref-type="fig"}**), LVPWs (**Figure [1I](#F1){ref-type="fig"}**), and LV Vold (**Figure [1J](#F1){ref-type="fig"}**). Valsartan (20 mg/kg) also increased CO (**Figure [1D](#F1){ref-type="fig"}**). However, neither SXNI nor valsartan markedly affected LVPWd (**Figure [1H](#F1){ref-type="fig"}**), heart rate (**Figure [1L](#F1){ref-type="fig"}**), and LV Mass (**Figure [1M](#F1){ref-type="fig"}**) compared with the I/R group. Color images were acquired in color Doppler mode at 18 h after reperfusion to evaluate the effects of SXNI on coronary blood flow (**Figure [2A](#F2){ref-type="fig"}**). As expected, in the I/R group, AV peak velocity (**Figure [2B](#F2){ref-type="fig"}**), AV peak pressure (**Figure [2C](#F2){ref-type="fig"}**), and AoV VTI (**Figure [2D](#F2){ref-type="fig"}**) were significantly lower than those in the Sham group. However, these deficiencies were markedly improved by SXNI (2.5 and 12.5 mL/kg, **Figures [2B](#F2){ref-type="fig"}--[D](#F2){ref-type="fig"}**) and valsartan (20 mg/kg) significantly increased AV peak velocity (**Figure [2B](#F2){ref-type="fig"}**) and AV peak pressure (**Figure [2C](#F2){ref-type="fig"}**). Collectively, these data suggest that SXNI treatment improves cardiac performance in the model of I/R injury.

![Echocardiographic evaluation of SXNI on cardiac function in MIRI mice. After 30 min of ischemia and 18 h of reperfusion, the curative effect of SXNI (2.5 mL/kg), SXNI (12.5 mL/kg), and valsartan (20 mg/kg) on cardiac function was evaluated. **(A)** Representative images of echocardiography. Cardiac performance was determined by echocardiography with different groups. **(B)** LVEF %, **(C)** LVFS %, **(D)** CO, **(E)** stroke volume, **(F)** LVIDd, **(G)** LVIDs, **(H)** LVPWd, **(I)** LVPWs, **(J)** LV Vold, **(K)** LV Vols, **(L)** heart rate, and **(M)** LV Mass were measured in M-mode. Results were presented as mean ± SEM (*n* = 7-10). ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. Sham group, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. I/R group. (LV, left ventricular; EF, ejection fraction; FS, LV fractional shortening; CO, cardiac output; LVIDd, LV internal dimensions at diastole; LVIDs, LV internal diameter systole; LVPWd, LV posterior wall diastole; LVPWs, LV posterior wall systole; LV Vols, LV systole volume; LV Vold, LV diastole volume).](fphar-09-00312-g001){#F1}

![Effects of SXNI on coronary blood flow in MIRI mice. After 30 min of ischemia and 18 h of reperfusion, the curative effect of SXNI (2.5 and 12.5 mL/kg) and valsartan (20 mg/kg) on coronary blood flow was evaluated. **(A)** Representative echocardiography images of coronary blood flow were determined with different groups. **(B)** AV peak velocity, **(C)** AV peak pressure, and **(D)** AoV VTI were measured in Color Doppler mode. Results were presented as mean ± SEM (*n* = 7--10). ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. Sham group, ^∗^*P* \< 0.05 vs. I/R group. (AV Peak Vel, aortic valve peak velocity; AoV VTI, aorta velocity-time integral mean velocity).](fphar-09-00312-g002){#F2}

SXNI Attenuated Myocardial Injury in MIRI Mice
----------------------------------------------

To investigate the effects of SXNI on MIRI, myocardial infarction size, histopathology and serum LDH, AST, CK-MB, and CK release were measured. After 30 min ischemia and 24 h reperfusion, the myocardial infarction size, morphology and serum LDH, AST, CK-MB, and CK activities were obviously altered compared with the sham group, resulting in myocardial injury (**Figure [3](#F3){ref-type="fig"}**). However, treatment groups significantly reduced myocardial infarct size (**Figures [3A,B](#F3){ref-type="fig"}**). Simultaneously, the histopathological examination of heart tissues from I/R group exhibited widespread myocardial structural disarray, increased necrosis and fusion area, and many inflammatory cells infiltrating the myocardial tissue, which were indicated with yellow arrows (**Figure [3C](#F3){ref-type="fig"}**). In contrast, the damaged histological features and cardiac structure were distinctly ameliorated after administration with SXNI (2.5 mL/kg) and valsartan (20 mg/kg) (**Figure [3C](#F3){ref-type="fig"}**). In contrast with I/R group, SXNI (2.5 mL/kg) and valsartan (20 mg/kg) markedly lowered the activities of LDH, AST, CK-MB, and CK in serum (**Figures [3D](#F3){ref-type="fig"}--[G](#F3){ref-type="fig"}**).

![Effects of SXNI on myocardial injury in MIRI mice. After 30 min of ischemia and 24 h of reperfusion, the effect of SXNI on myocardial injury was evaluated. **(A)** TTC staining determined the effect of SXNI (2.5 mL/kg) and valsartan (20 mg/kg) on myocardial infarct area. **(B)** Bar graphic representation of myocardial infarct size (*n* = 4). **(C)** Representative H&E staining (100× and 400× magnification) pictures indicating the histopathological changes in I/R model as well as that caused by SXNI and valsartan. Yellow arrows indicated myocardium damage sections (*n* = 4). **(D--G)** The effect of SXNI and valsartan on release of LDH, AST, CK-MB, and CK in serum at the end of reperfusion (*n* = 6). Results were presented as mean ± SEM. ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. Sham group, ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. I/R group.](fphar-09-00312-g003){#F3}

SXNI Decreased Infarction Volumes in CIRI Mice
----------------------------------------------

Cerebral ischemic-reperfusion caused significant cerebral infarct. At 24 h after initiation of ischemic stroke, SXNI at both 0.5 and 2.5 mL/kg significantly reduced infarct volumes caused by cerebral ischemic-reperfusion damage. Remarkably, SXNI at 12.5 mL/kg almost completely eliminated the cerebral infarction. Similar to SXNI, the cerebral infarction volumes were significantly reduced by edaravone, a neuroprotective agent used clinically and serving as a positive control (**Figures [4A,B](#F4){ref-type="fig"}**).

![Effects of SXNI on cerebral injury in CIRI mice. After 90 min of ischemia and 24 h of reperfusion, the curative effect of SXNI on cerebral injury was evaluated. **(A)** Representative images of brain sections stained with TTC. After reperfusion for 24 h, five groups of mice were treated intravenously with saline (model), SXNI at 0.5, 2.5, and 12.5 mL/kg as well as edaravone (9 ml/kg), respectively. Ischemic infarctions (white area) were detected in all groups. **(B)** At 24 h after stroke, the percentage of infarct volumes was quantified (*n* = 6--8). Results were presented as mean ± SEM. ^∗∗^*P* \< 0.01 vs. I/R group.](fphar-09-00312-g004){#F4}

Transcriptome Identification of DEGs in MIRI and CIRI Mice After SXNI Treatment
-------------------------------------------------------------------------------

To identify gene targets of SXNI in brain and heart, the left ventricular myocardium sections of MIRI and the brain slices from CIRI with or without SXNI treatment were subjected for high-throughput sequencing analyses. After mapping the sequencing reads to the reference genome, the relative expression levels of the transcripts were calculated in FPKM. Overall, there were 26,586 expressed genes in the CIRI +SXNI brain samples and 26,390 expressed genes in CIRI brain samples, whereas 24,444 expressed genes in the MIRI +SXNI heart samples and 24,347 expressed genes in the MIRI samples. Furthermore, 329 significantly altered DEGs with twofold or greater changes and *P*-value less than 0.05 were screened out in CIRI +SXNI samples over the CIRI samples. That included 121 upregulated and 208 downregulated genes (**Figure [5A](#F5){ref-type="fig"}**). In MIRI +SXNI samples over the MIRI samples, 94 significantly differential expressions, with 28 upregulated and 66 downregulated genes, were detected (**Figure [5B](#F5){ref-type="fig"}**). The details of the significantly DEGs are listed in **Supplementary Tables [S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}** and the overall gene expression profiles of their hierarchical cluster are presented in **Figures [5C,D](#F5){ref-type="fig"}**.

![Differentially expressed gene (DEGs) of SXNI vs. CIRI and SXNI vs. MIRI. The overall distribution of differentially expressed genes (fold change ≥ 2 and *p*-Value ≤ 0.05) was reflected by the volcanic map. The *X*-axis represents the changes of gene expression in different samples and *Y*-axis represents the statistical significance of the difference in the gene expression. The up-regulated genes were in red and down-regulated genes in green. **(A)** The distribution of differently expressed genes between SXNI vs. CIRI samples, while **(B)** for the SXNI *vs.* MIRI samples. Hierarchical clustering representing the overall profiles of the transcripts that were significantly and differently expressed in **(C)** SXNI vs. CIRI samples, and **(D)** SXNI vs. MIRI samples.](fphar-09-00312-g005){#F5}

The Shared Pathways and Functions Between MIRI and CIRI After SXNI Treatment
----------------------------------------------------------------------------

The significantly differentially expressed DEGs were submitted to IPA to execute core analysis. In separate groups of CIRI (**Figure [6A](#F6){ref-type="fig"}**) and MIRI (**Figure [6B](#F6){ref-type="fig"}**) after SXNI administration, upregulated (in red)- and downregulated (in blue)-genes and their corresponding top 10 pathways were displayed. Among the DEGs in both, two overlapping genes are detected between the brain tissues (SXNI vs. CIRI) and myocardium (SXNI vs. MIRI) (**Figure [2](#F2){ref-type="fig"}**), which are *Calca* (ENSMUSG00000030669) and *Tnfrsf12a* (ENSMUSG00000023905). *Calca* is associated with Parkinson diseases ([@B9]) and essential hypertension ([@B54]), while *Tnfrsf12a* is an important molecule in cardiac hypertrophy disease ([@B57]), cardiac shock ([@B96]) retinal inflammation ([@B1]), and atherosclerosis-related diseases ([@B65], [@B64]; [@B63]; [@B25]). Top 10 canonical pathways and top 6 functions were listed by the descending -log(*p*-value) score (**Figures [6C](#F6){ref-type="fig"}--[F](#F6){ref-type="fig"}**). The most impacted top 10 canonical signaling pathways with a descending order in brain were catecholamine biosynthesis, role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis, gas signaling, role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis, atherosclerosis signaling, intrinsic prothrombin activation pathway, cAMP-mediated signaling, G-protein coupled receptor signaling, PCP pathway and eicosanoid signaling. The most related top 10 canonical signaling pathways in turn in heart were atherosclerosis signaling, granulocyte adhesion and diapedesis, agranulocyte adhesion and diapedesis, HMGB1 signaling, aryl hydrocarbon receptor signaling, role of JAK1 and JAK3 in γc cytokine signaling, xenobiotic metabolism signaling, acute phase response signaling, fatty acid α-oxidation and IL-17 signaling. Notably, the pathway of atherosclerosis signaling and the function of inflammatory response were affected in both I/R brain tissues and myocardium (**Figures [6C](#F6){ref-type="fig"}--[F](#F6){ref-type="fig"}**), indicating that they might serve as a common mechanism in response to SXNI treatment for both CIRI and MIRI. Detailed depiction of AS signaling based on the gene expression data was shown in **Figure [7A](#F7){ref-type="fig"}** (brain genes in blue, heart genes in yellow and both in green). These genes included *Pla2g2f, Il1f9, Col1a1, Col1a2*, and *Col3a1* in the brain tissues (in yellow), while *SELP, SELE, IL6* and *IL1A* were identified in the myocardium (in blue), and *Tnfrsf12a* in both (in green). Interestingly, these 10 highly regulated genes by SXNI were also relevant to inflammatory response. The relationship between inflammatory response and atherosclerosis signaling with the 10 genes in separate groups was shown (**Figure [7B](#F7){ref-type="fig"}**). Collectively, they provide new molecular insights into the known notion that active ingredients of Ginkgo biloba extract in SXNI play an important role in protecting against cardio- and cerebral vascular diseases.

![Shared mechanisms of SXNI on both MIRI and CIRI. DEGs with top 10 pathways in groups of **(A)** CIRI+SXNI vs. CIRI, and **(B)** MIRI+SXNI vs. MIRI (upregulated genes in red color, downregulated genes in blue and two amplifying common genes). The top 10 canonical pathways (CP) in groups of **(C)** CIRI+SXNI vs. CIRI, and **(D)** MIRI+SXNI vs. MIRI. Atherosclerosis signaling was shared in both groups. The top 6 functions in groups of **(E)** CIRI+SXNI vs. CIRI, and **(F)** MIRI+SXNI vs. MIRI. Inflammatory response was existed in both groups. The importance was ordered from top to bottom by --log (*p*-value).](fphar-09-00312-g006){#F6}

![Validation of SXNI regulated genes in inflammatory and atherosclerosis signaling. **(A)** The details of atherosclerosis signaling with DEGs in two groups of SXNI vs. CIRI (blue) and SXNI vs. MIRI (yellow) were shown, *TNFRSF12A* was shared in both groups (green). **(B)** The relationship between inflammatory response and atherosclerosis signaling with the 10 genes was displayed. **(C**) *TNFRSF12A* and *IL6* in atherosclerosis signaling in heart were validated. **(D)** *TNFRSF12A, Pla2g2f*, and *Col3a1* in atherosclerosis signaling in brain were validated. Results were presented as mean ± SD, *n* = 3. ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01 vs. I/R group.](fphar-09-00312-g007){#F7}

Validation of DEGs in AS Signaling
----------------------------------

Aiming to validate the results of transcriptome analysis, five genes in AS signaling, including *Tnfrsf12a, IL-6* in hearts (**Figure [7C](#F7){ref-type="fig"}**) and *Tnfrsf12a, Pla2g2f*, and *Col3a1* in brains (**Figure [7D](#F7){ref-type="fig"}**), were extracted for qPCR validation. The qPCR results were consistent with the transcriptome data, suggesting the transcriptome data were reliable. Of note, identical to the transcriptome results, *Tnfrsf12a* expression in I/R heart was downregulated 55.6% (**Figure [7C](#F7){ref-type="fig"}**) whereas in I/R brain was upregulated 130.9% (**Figure [7D](#F7){ref-type="fig"}**) by SXNI, respectively.

Discussion
==========

There are several new discoveries in this study: (1) this is the first report that SXNI, another EGB, had a protective effect on both CIRI-induced cerebral infarction and MIRI-induced myocardial infarction and cardiac dysfunction; (2) RNA-seq analysis identified 329 DEGs in SXNI vs. CIRI and 94 DEGs in SXNI vs. MIRI, with two shared genes of *TNFRSF12A* and *Calca*; (3) IPA analysis revealed top 10 canonical signaling pathways including catecholamine biosynthesis, atherosclerosis signaling, cAMP-mediated signaling, G-protein coupled receptor signaling and eicosanoid signaling, and top 6 functions such as organismal injury and abnormalities, neurological disease and inflammatory response in SXNI vs. CIRI, whereas top 10 canonical signaling pathway including atherosclerosis signaling, HMGB1 signaling, aryl hydrocarbon receptor signaling and fatty acid α-oxidation, and top 6 functions including inflammatory disease, inflammatory response and immunological disease in SXNI vs. MIRI; (4) atherosclerosis signaling and inflammatory response merged as a common theme in both by comparison. Ten key regulated genes (including *Pla2g2f, Il1f9, Col1a1, Col1a2*, and *Col3a1* in the brain, while *SELP, SELE, IL6*, and *IL1A* in the myocardium, and *Tnfrsf12a* in both) are correlative with atherosclerosis signaling and inflammatory response.

Inflammatory response is by now well recognized as a critical contributor for the initiation and development of atherosclerotic cardiovascular disease ([@B44]), and contributes to ischemic cardiovascular disease linking stroke to cardiac dysfunction ([@B43]; [@B16]). Two recent studies reported that canakinumab targeting the interleukin-1β (IL-1β) immunity pathway was regarded as new anti-inflammatory strategies to reduce atherosclerotic disease ([@B77]) and incident lung cancer with atherosclerosis in patient ([@B78]), proving that anti-inflammatory therapy is a valid curative method to lower cardiovascular events. These examples directly support the notion that inflammatory response is capable of serving as the common mechanism for SXNI to treat both CIRI and MIRI. In addition, atherosclerosis signaling, another common mechanism of SXNI action, is recorded as a canonical pathway in IPA under the pathway category of cardiovascular signaling and disease-specific pathways, indicating that SXNI may exert an effect on atherosclerosis by targeting the ten identified genes, which need to be experimentally verified in future studies.

It is worth noticing that the ten SXNI-regulated genes in atherosclerosis signaling are also related to inflammatory response, especially the *Tnfrsf12a* gene, which was shared in both brain and heart tissues. Also called as fibroblast growth factor-inducible 14 (Fn14), *Tnfrsf12a* is the smallest but most powerful TNFR superfamily member described so far, which is a plasma membrane receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK and/or *Tnfrsf12a* has been identified as potential therapeutic targets in numerous diseases, including (1) cancers such as ([@B105]) cancer-induced cachexia ([@B34]), glioblastoma ([@B73]), melanoma ([@B115]), gastric cancer ([@B38]), ovarian cancer ([@B19]), triple-negative breast cancer ([@B116]), and esophageal adenocarcinoma ([@B98]); (2) liver diseases such as alcoholic hepatitis ([@B3]) and non-alcoholic fatty liver disease (NAFLD) ([@B52]); (3) kidney diseases such as renal ischemia reperfusion injury ([@B32]), fibrotic kidney disease ([@B107]; [@B103]) and kidney injury ([@B72]; [@B81]; [@B99]); (4) and a variety of other diseases such as graft- vs. -host disease (GVHD) ([@B17]; [@B58]), atopic dermatitis (AD) and psoriasis ([@B86]), acute intestinal inflammation ([@B21]), neuropsychiatric disease ([@B102]), lupus nephritis ([@B61]), bullous pemphigoid ([@B49]), cutaneous disease ([@B23]), chronic colitis ([@B88]), amyotrophic lateral sclerosis ([@B8]), myotonic dystrophy ([@B108]). Importantly, *Tnfrsf12a* receptor protects against right heart fibrosis and dysfunction ([@B69]) and cardiomyocyte proliferation ([@B68]) in heart-related diseases. On the other hand, *Tnfrsf12a* expression in brain is regarded as a prognostic/predictive biomarker of brain metastasis ([@B59]), and protects neurodegeneration ([@B76]) and cerebral ischemia ([@B112]). Interestingly, our results showed that *Tnfrsf12a* was upregulated in SXNI vs. CIRI group, while downregulated in SXNI vs. CIRI group, remarkably coincident with the detrimental or beneficial functions of this gene in heart and brain, respectively. This may also attribute to the bidirectional effect of *Tnfrsf12a*, such as pro-inflammatory ([@B11]) and anti-inflammatory effect ([@B86]). In certain instances of acute injury, *Tnfrsf12a* signaling would be transient in nature and beneficial. However, in conditions of chronic tissue injury, *Tnfrsf12a* expressed in high levels could result in harmful, pathological effects ([@B104]). In addition, for one thing, mice lacking *Tnfrsf12a* substantially reduced right ventricular fibrosis and dysfunction ([@B69]). For another, deletion of *Tnfrsf12a* promotes blood brain barrier (BBB) disruption and increases neuronal cell death ([@B101]). Taken together, *Tnfrsf12a* may serve as a common therapeutic target for SXNI to treat both CIRI and MIRI, which should be further elucidated in the future.

In addition to the shared inflammation-atherosclerosis signaling pathways in I/R brain and heart by SXNI discussed above, our transcriptome analysis also indicated a number of interesting unique targeting genes/pathways in each tissue. For example, catecholamine biosynthesis and organismal injury and abnormalities are ranked as number one disease and function in I/R brain treated with SXNI, respectively (**Figures [6C,E](#F6){ref-type="fig"}**). Inhibition of catecholamine biosynthesis has been shown to reduce acute ischemic stroke ([@B100]) and this may provide a new light for SXNI to treat CIRI. Protection of brain from injury and related symptoms are the most documented beneficial effects by EGB ([@B10]; [@B20]; [@B70]; [@B84]; [@B79]; [@B2]; [@B89]; [@B92]; [@B66]; [@B4]; [@B48]; [@B106]; [@B35]; [@B91]). G-protein coupled receptor (GPCR) are the most abundant receptor type in the central nervous system and are linked to platelet activation, BBB function and endothelial dysfunction ([@B28]), leading to another insight of SXNI for CIRI. HMGB1 is a danger signal that senses cell damage especially in cardiac ischemia, and is an important candidate biomarker predicting the risk of cardiovascular events in clinic ([@B74]). Besides, aryl hydrocarbon receptor signaling plays a key role in myocardium reperfusion-triggered stress response ([@B94]). SXNI effects on HMGB1 signaling and aryl hydrocarbon receptor signaling, particularly regarding the MIRI, should be paid more attention in further studies.

Although SXNI could significantly protect both CIRI and MIRI in our experiments, it is still possible that it is more inclined to target CIRI than MIRI, as more transcriptome DEGs were identified in SXNI vs. CIRI than SXNI vs. MIRI. SXNI at high dose even reversed the brain damage completely, consistent with the fact that more EGB-related beneficial reports are on brain and to a much less extent, on the heart. In previous studies, EGB was well documented to treat cerebral- and myocardial ischemia, and SXNI, a clinically proven prescription of EGB, provides a good model to further explore the major active ingredients. Our ongoing study on identification of the main ingredients (mainly derived from flavonols and terpene trilactones) and their selective pharmacological action on brain and heart should facilitate a deeper understanding of the brain-heart protection mechanisms of EGB in the future.

Conclusion
==========

Our RNA-seq and network pharmacology analyses revealed for the first time that SXNI ameliorates both CIRI-induced cerebral infarction and MIRI-induced myocardial infarction. The common mechanisms shared in both are linked with atherosclerosis signaling and inflammatory response with at least the following target genes: *Tnfrsf12a, Pla2g2f, Il1f9, Col1a1, Col1a2*, and *Col3a1* in brain, while *Tnfrsf12a, SELP, SELE, IL6*, and *IL1A* in myocardium. Besides, the opposite regulation of *Tnfrsf12a* by SXNI in CIRI and MIRI is consistent with the documented function of this gene in the respective tissues. Overall, this study provides a new understanding of SXNI in clinical application on I/R-induced cardio- and cerebral vascular diseases.
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